First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
暂无分享,去创建一个
[1] R. Motzer,et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Figlin,et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .
[3] R. Figlin,et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors , 2007 .
[4] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[5] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[6] R. Figlin,et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.